Biotech News

Xtant Medical Reports Third Quarter 2026 Financial Results and Announces Board-led Strategic Review Process

Xtant Medical (XTNT)Xtant MedicalEarnings

Board reiterates commitment to improving performance and maximizing stockholder value; has been actively involved in a comprehensive review of a broad range of strategic, operational, and financial alternatives. BELGRADE, Mont., Nov. 16, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc.

Related news

Xtant Medical

Orthopedic Surgical Products Company Xtant Medical develops and distributes surgical products for spinal and other orthopedic procedures. Biologics and Implants The portfolio includes bone grafts, biologic materials, spinal fixation systems, and related surgical instruments. Hemostasis Expansion An exclusive U.S. distribution agreement...

Recent company news

Stock data

Close
0.22 USD
Market cap
65.22M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States